Agis Industries takes 19.9% stake in Israel's Meditor Pharmaceuticals

3 September 2000

Agis Industries has invested about $2 million, via equity andconvertible stock, to purchase a 19.9% stake in Meditor Pharmaceuticals and also has an option to increase its future holding in the firm to about 25%. Meditor is an Israeli company involved in the development of unique drugs in the area of cardiovascular medicine and neurology. Agis has also acquired the remaining minority interests in its subsidiary Clay Park Labs in the USA, thus acquiring full control of the latter.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight